Bainbridge Kathleen E, Cowie Catherine C, Rust Keith F, Fradkin Judith E
Social & Scientific Systems, Silver Spring, Maryland, USA.
Diabetes Care. 2008 Sep;31(9):1754-60. doi: 10.2337/dc07-2010. Epub 2008 May 28.
Performance measures are tools for assessing quality of care but may be influenced by patient factors. We investigated how currently endorsed performance measures for glycemic control in diabetes may be influenced by case mix composition. We assessed differences in A1C performance measure threshold attainment by case mix factors for A1C >9% and examined how lowering the threshold to A1C >8% or >7% changed these differences.
Using data from the 1999-2002 National Health and Nutrition Examination Survey for 843 adults self-reporting diabetes, we computed the mean difference in A1C threshold attainment of >9, >8, and >7% by various case mix factors. The mean difference is the average percentage point difference in threshold attainment for population groups compared with that for the overall population.
Diabetes medication was the only factor for which the difference in threshold attainment increased at lower thresholds, with mean differences of 5.7 percentage points at A1C >9% (reference), 10.1 percentage points at A1C >8% (P < 0.05), and 14.1 percentage points at A1C >7% (P < 0.001).
As 87% of U.S. adults have A1C <9%, a performance measure threshold of >9% will not drive major improvements in glycemic control. Lower thresholds do not exacerbate differences in threshold attainment for most factors. Reporting by diabetes medication use may compensate for heterogeneous case mix when a performance measure threshold of A1C >8% or lower is used.
绩效指标是评估医疗质量的工具,但可能会受到患者因素的影响。我们研究了目前认可的糖尿病血糖控制绩效指标可能如何受到病例组合构成的影响。我们评估了糖化血红蛋白(A1C)>9%时,不同病例组合因素在A1C绩效指标阈值达成方面的差异,并研究将阈值降低至A1C>8%或>7%如何改变这些差异。
利用1999 - 2002年全国健康与营养检查调查中843名自述患有糖尿病的成年人的数据,我们计算了不同病例组合因素在A1C阈值达成>9%、>8%和>7%时的平均差异。平均差异是各人群组在阈值达成方面与总体人群相比的平均百分点差异。
糖尿病用药是唯一一个在较低阈值下阈值达成差异增加的因素,在A1C>9%(参考值)时平均差异为5.7个百分点,在A1C>8%时为10.1个百分点(P<0.05),在A1C>7%时为14.1个百分点(P<0.001)。
由于87%的美国成年人糖化血红蛋白(A1C)<9%,>9%的绩效指标阈值不会推动血糖控制取得重大改善。对于大多数因素而言,较低的阈值不会加剧阈值达成方面的差异。当使用A1C>8%或更低的绩效指标阈值时,按糖尿病用药情况报告可能会弥补病例组合的异质性。